Why the study?
Does fluorouracil, epirubicin, and cyclophosphamide (FEC2) chemotherapy improve outcomes compared to cyclophosphamide, methotrexate, and fluorouracil (CMF) chemotherapy in premenopausal women with axillary node-positive operable breast cancer?
Does fluorouracil, epirubicin, and cyclophosphamide (FEC2) chemotherapy improve outcomes compared to cyclophosphamide, methotrexate, and fluorouracil (CMF) chemotherapy in premenopausal women with axillary node-positive operable breast cancer?
FEC2 is preferable to CMF as adjuvant chemotherapy for premenopausal patients with operable axillary node-positive breast cancer.
Supports FEC2 over CMF for premenopausal node-positive breast cancer; confirms benefit of epirubicin substitution in adjuvant regimens.
We conclude that the FEC2 regimen, in which epirubicin replaced the methotrexate in CMF, is the preferable adjuvant chemotherapy regimen for premenopausal patients with operable axillary node-positive breast cancer.
No takes yet. Share an insight, caveat, or question.
Coombes et al. (1996) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: